Bradley A. McGregor, MD, sheds light on recently approved agents, as well as a multitude of novel therapies on the horizon, that appear to spell out a promising future for the treatment of patients with nonmetastatic castration-resistant prostate cancer.
Toni K. Choueiri, MD, discusses the novel coronavirus disease, which continues to impact the care of patients with metastatic renal cell carcinoma and other cancers in a multitude of ways.
David A. Reardon, MD, discusses the design of a phase 1/2 trial with INO-5401 and INO-9012 in glioblastoma.
Praful K. Ravi, MD, discusses the evolving treatment landscape of advanced bladder cancer.
Bradley McGregor, MD, discusses some of the recent approaches that have emerged in bladder cancer and renal cell carcinoma, as well as anticipated developments in each field.
David A. Reardon, MD, discusses the role of INO-5401 and INO-9012 in glioblastoma.
Guru P. Sonpavde, MD, discusses several trials in the field of first-line metastatic urothelial cancer that are testing combinations with gemcitabine/platinum-based therapy followed by maintenance avelumab.
Guru P. Sonpavde, MD, discusses the utility of combining anti-VEGF and anti–PD-1 agents in metastatic urothelial carcinoma.
Ursula A. Matulonis, MD, discusses the potential role of combined positive score as a biomarker in advanced recurrent ovarian cancer.
Paul L. Nguyen, MD, discusses the role of radiation in high-risk prostate cancer and ongoing research efforts in the space.
Matthew S. Davids, MD, MMSc, discusses remaining questions with umbralisib plus ibrutinib in chronic lymphocytic leukemia and mantle cell lymphoma.
Praful K. Ravi, MD, discusses the emergence of immunotherapies, FGFR inhibitors, and antibody-drug conjugates and how they dramatically evolved the metastatic urothelial cancer treatment paradigm.
Savolitinib demonstrated encouraging efficacy and an improved safety profile over sunitinib in patients with MET-driven papillary renal cell carcinoma.
Toni K. Choueiri, MD, discusses current and emerging treatment options for patients with metastatic renal cell carcinoma.
Caron Jacobson, MD, discusses the initial ZUMA-5 findings and the next steps with axicabtagene ciloleucel in follicular lymphoma and marginal zone lymphoma.
Paul G. Richardson, MD, discusses the patient population analyzed in the first-in-human phase 1 trial of the CELMoD CC-92480.
Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.
Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.
Sara M. Tolaney, MD, MPH, discusses the unmet need with regard to effectively preventing central nervous system recurrence in HER2-positive breast cancer.
Mark M. Awad, MD, PhD, discusses the findings from the study, the importance of identifying patients with METex14 mutations, and the importance of understanding acquired resistance in NSCLC.
Caron Jacobson, MD, discusses the safety profile of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.
Immunoglobulin light chain amyloidosis is the most common form of systemic amyloidosis and is characterized by rapidly progressive organ failure and eventually patient demise, if not promptly recognized and treated.
Julia K. Rotow, MD, discusses the results of an ongoing phase 1/2 trial evaluating the safety and efficacy of osimertinib in combination with gefitinib as a first-line treatment for patients with stage IV EGFR-mutant non–small cell lung cancer.
Corey S. Cutler, MD, MPH, FRCPC, discusses remaining challenges in graft-versus-host disease.
Toni K. Choueiri, MD, discusses the findings from the phase 1/2 trial, the clinical implications of targeting HIF-2α in kidney cancer, and the potential utility of MK-6482 in clear cell RCC.
Sara M. Tolaney, MD, MPH, discusses sequencing strategies in metastatic HER2-positive breast cancer.
Sara M. Tolaney, MD, MPH, discusses remaining questions with CDK4/6 inhibitors in hormone receptor–positive, HER2-negative metastatic breast cancer.
In an effort to share some of the evolving knowledge about COVID-19 and how it is impacting the healthcare system on a global scale, the Uromigos group discusses statistics, strategies, and new studies as they relate to COVID-19 and patients with genitourinary cancers.
Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses combinations with venetoclax (Venclexta) in acute myeloid leukemia (AML).
Anis Hamid, MBBS, discusses potential combination with docetaxel in metastatic hormone-sensitive prostate cancer subtypes.
